CincyTech USA

02/25/2026

The energy at this morning’s "Welcome to the Ecosystem" event was incredible. Huge thanks to Cintrifuse for hosting such a high-impact gathering and bringing the community together.

​Ashley, Logan, and Will had a fantastic time connecting with everyone. We met students just beginning to explore the world of tech, seasoned founders, and key players navigating every stage of the innovation journey.

​The talent and grit in this room is what makes our community so strong, and we left today feeling inspired. Whether you're building, investing, or just curious about what’s next, we’re glad you’re here.

​Let’s keep the momentum going! 🔥

02/19/2026

Big wins for the 513! 💥

Huge congratulations to our portfolio company, Losant, on their acquisition by SUSE!

From early-stage startup to a global Industrial IoT leader, we’ve loved being part of the journey.

Why is this a game-changer?

It’s all about the "Tiny Edge." 🌐

While most IoT solutions stop at the gateway, Losant reaches directly into sensors and machines where the physical world meets the digital. By joining forces with SUSE, they are creating the world’s first full-stack, open-source automation platform.

What this means for the industry:

🔹 Bridging OT & IT: Seamlessly connecting factory-floor hardware with enterprise-level AI.

🔹 Open Source Economics: Breaking vendor lock-in so companies can innovate faster and more affordably.

🔹 Real-Time Intelligence: Decisions happen in milliseconds directly on the device.

This move isn't just a win for Losant; it’s a massive proof point for the talent and innovation coming out of Cincinnati. 📈🚀

Read more here: https://www.suse.com/news/suse-acquires-losant/

02/06/2026

New to the scene? 🔌✨

If you’re new to Cincinnati or just starting your journey into the innovation world, Welcome to the Ecosystem is your "where-to-start" guide.

We’re taking over a table at Union Hall on Feb 25th to help you cut through the noise. Come find out how to get involved, meet the community, and learn how CincyTech helps local founders grow.

Where to find us:
🗓 Wednesday, Feb 25th
⏰ 10am - 12pm
📍 Union Hall (Beer Hall)
🔗 Register here: https://luma.com/zht10jt0

Will we see you there? 👀

StartupCincy

02/05/2026

We are thrilled to share that CincyTech portfolio company Eyas Medical Imaging has officially received FDA 510(k) clearance for its Ascent3T™ Neonatal MRI System.

This is a game-changer for neonatal care. The Ascent3T is the world's first high-field, 3 Tesla MRI system designed specifically for the smallest and most vulnerable patients.

Why this matters:

✨ Point-of-Care Imaging: Its compact, virtually helium-free design allows it to be installed directly inside the NICU.

✨ Reduced Risk: Eliminates the need to transport fragile newborns through hospital hallways to imaging suites.

✨ Unmatched Precision: Provides high-resolution 3T imaging of the brain, lungs, heart, and abdomen, tailored specifically to infant anatomy.

Born out of world-class research at Cincinnati Children's, Eyas is a prime example of how local innovation is solving global healthcare challenges.

Congratulations to Matt Storer, Dr. Charles Dumoulin, and the entire Eyas team on this incredible achievement.

Read the full announcement here:

Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Ascent3T™ Neonatal Magnetic Resonance Imaging (MRI) ...

02/04/2026

A Powerful Milestone for Ohio Innovation 🚀🌰

We are incredibly proud to celebrate a major milestone for one of our portfolio companies, Genetesis. After 12 years of pioneering magnetocardiography technology in the City of Mason, Ohio, the company has officially exited following the sale of its business assets to a multibillion-dollar technology leader.

While we celebrate this successful acquisition, we are equally thrilled to congratulate Peeyush Shrivastava on his next chapter as a Principal at The O.H.I.O. Fund. In a wonderful full-circle moment, Peeyush will be working alongside our former CEO, Mike Venerable, to lead the charge in funneling more investment and support into the Greater Cincinnati area.

This isn’t just a win for Genetesis; it’s a win for Ohio. A global player recognizing the value of technology developed right here in our backyard proves our region competes at the highest level. Perhaps even more importantly, we are retaining the visionary talent that built this success

Peeyush joining the O.H.I.O. Fund is a prime example of a thriving ecosystem in action ➡️ where the expertise gained over a decade of building is recycled back into the community to drive the next wave of innovation.

Peeyush, it has been a privilege to support you from the early days. Thank you for your dedication to the Mason tech community over the last 12 years. We are honored to have been part of your journey and can’t wait to see the impact you’ll continue to make for Ohio entrepreneurs!

To read the full Cincinnati Business Courier Cincy Inno article👉

Startup backed by Mark Cuban, CincyTech exits >> See the full article below ⬇️

01/23/2026

Earlier this month, the CincyTech team had the chance to take over the 🧠Learning Lab at the University of Cincinnati's 1819 Innovation Hub to dive deep into the principles of Jim Collins’ book, "Good to Great."

We didn't just talk theory; we got to work.

In high-growth environments, complexity is the default, but focus beats complexity. We spent the day identifying our "One Big Thing," the core mission that allows us to say no to distractions so we can say yes to impact.

Our Key Takeaways:

➡️ Alignment Multiplies Energy: When our team is aligned on our mission and vision, every ounce of effort is amplified.

➡️ The Flywheel Effect: Momentum is earned. You don't lose momentum if you don't stop pushing; you just have to keep the right pressure on the right points.

➡️ Friction is Feedback: We’re leaning into the challenges, using them as data points to refine our process.

➡️ The Intersection of Success: True momentum follows when passion, excellence, and our economic engine meet.

The work doesn't end when we leave the 1819 Hub. We’re already back at it, with follow-up sessions on the calendar to keep narrowing our focus. By staying disciplined about what we do best, we’re ensuring every member of our team feels the pride and purpose that come with true alignment.

A huge thank you to the team at the 1819 Innovation Hub and Learning Lab for hosting us and facilitating such a productive environment. Specifically, thank you to Nicholas Partridge, Kurt Myers, and Rebecca Rudolph for your guidance and support in making this session happen.

Greatness is a process of discipline, and we’re just getting started. 📈🔥

01/23/2026

Huge congratulations to Aaron Chow and Anu Vora for being named to the OhioX Next25!

This list recognizes the individuals shaping what’s next for our state’s tech ecosystem. We were honored to submit their nominations and are thrilled to see their hard work recognized:

✨Aaron Chow, Founder & CEO of our portfolio company, Vixiv, continues to push the boundaries of what’s possible within our portfolio.

✨Anu Vora is a dedicated leader whose contributions are making a lasting mark on the tech landscape in Ohio and beyond.

The energy and innovation these two bring to the table are exactly what drive our ecosystem forward. Well deserved!

Meet all of Ohio's Next25: https://www.ohiotechnews.com/meet-next25-2025/

01/20/2026

JPM 2026 🌉 marked a fundamental shift for the biotech sector: a move away from speculative "storyline" hype toward tangible, data-driven validation.

Our Life Sciences Partner, Kenny Morand, is back from San Francisco with strategic insights on what this "new reality" means for the year ahead.

From landmark FDA pivots to the latest IPO "litmus tests," Kenny breaks down the critical quiet wins that will define 2026.

Key Takeaways:

♦️FDA Flexibility: A major shift in 21 CFR part 211 standards that will decrease clinical trial costs and increase speed.

♦️AI as Infrastructure: The $1B Lilly-Nvidia deal proves AI has moved beyond the buzzword phase into a core drug discovery backbone.

♦️The New "Lean and Mean": 2026 winners are focused on high-value therapeutic assets and measurable results.

Read Kenny's full analysis here 👉 https://cincytechusa.com/news/jpm-2026-the-shift-from-survival-to-cautious-optimism

01/20/2026

Big moves at CincyTech! 🚀

We are thrilled to announce that Sean Kwiat has been promoted to Vice President, Investments!

Since joining the team in 2015, Sean has been a driving force behind our investment strategy, contributing to over 100 early-stage financings and providing the financial acumen that helps our portfolio companies thrive.

In this new leadership role, Sean will head our investment team, driving deal flow and building a portfolio focused on high-impact technology and life sciences. Beyond capital allocation, he mentors our team of analysts and associates and plays a pivotal role in fund management. Sean will continue to be a dedicated partner to our founders, guiding them through early operational hurdles to secure follow-on institutional capital and achieve successful exits.

🎉Please join us in congratulating Sean on this well-deserved milestone! We can’t wait to see the impact he continues to make as we transform regional ideas into world-class companies.

01/19/2026

Today, we celebrate and honor the life and legacy of Dr. Martin Luther King Jr. It is a day to reflect on the strides we’ve made and, more importantly, the work that remains to be done.

Innovation is at its best when it serves everyone.

As we work to build world-class companies, CincyTech remains committed to fostering an ecosystem where opportunity is accessible to all. We believe the "arc of the moral universe" is bent toward justice through intentional economic and cultural inclusion.

In the startup world, we often talk about "transforming the future." Dr. King showed us that the most important transformation is one of equity, dignity, and belonging.

Let’s keep working together to build a future where every innovator has a seat at the table.

01/14/2026

The Biggest Win You Might Have Missed ⤵️

While the mega-deals are grabbing the front-page headlines, the most critical "on-the-ground" news for biotech startups happened in the regulatory fine print.

The FDA has officially announced a move toward more flexible guidance for cell and gene therapy (CGT) manufacturing.

➡️ The Technical Breakdown: For companies in Phase 2/3 trials, the FDA will no longer require full compliance with 21 CFR Part 211, the rigid manufacturing standards typically reserved for mass-produced, finished pharmaceuticals, before producing their investigational products.

Why is this a game-changer for biotech and the CincyTech portfolio?

✔️Accelerated Timelines: It removes the "one-size-fits-all" barrier for small-batch, individualized therapies and allows them flexibility to refine CMC over time.

✔️ Reduced Clinical Costs: Loosening these product requirements during later-stage efficacy trials means more capital can go toward testing the therapeutic hypothesis, not just the "paperwork" of manufacturing comparability studies.

✔️ Flexibility for Innovation: The FDA is now allowing "permissive release criteria" and minor manufacturing changes based on data comparability, rather than starting from scratch. FDA aims to advance innovative CGT products by communicating these flexible standards broadly, rather than on a case-by-case basis.

As Life Sciences Partner Kenny Morand put it, "The relaxing of clinical manufacturing protocols could both speed up and reduce clinical costs for gene therapy."

This isn't just a "hopeful comment"; it's a fundamental shift in how the industry will operate in 2026.

The US Food and Drug Administration (FDA) has announced it will take a flexible approach to reviewing all new cell and gene therapy (CGTs) biologics license applications (BLAs) to expedite the development of these products, rather than applying its flexibilities on a case-by-case basis. @

01/13/2026

Things are heating up at ! 🔥

Kenny Morand is on the ground for Day 2, and the buzz is all about "validation." We're seeing major moves that support the sector's recent 30% rise is more than just talk:

🚀 IPO Watch: Eikon Therapeutics (led by former Merck execs) is "testing the waters" for a public debut. If they win, we all win!
🤖 AI Power: Eli Lilly and Nvidia just announced a $1B joint investment in AI drug discovery!
🧬 Gene Therapy Wins: The FDA is easing manufacturing regulations to help get life-saving therapies to trials faster and cheaper.

It’s a hopeful morning in SF. This is the week that defines 2026 for the biotech industry. 📈